Summary

for people ages 18-75 (full criteria)
at La Jolla, California and other locations
study started
estimated completion

Description

Summary

This rollover study will provide open-label treatment with cenicriviroc and will assess the long-term safety of continued treatment with cenicriviroc in participants who participated in the CENTAUR study 652-2-203 [NCT02217475].

Official Title

Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)

Keywords

Nonalcoholic SteatohepatitisLiver CirrhosisNon-alcoholic Fatty Liver DiseaseLiver DiseasesFatty LiverTAK-652Cenicriviroc

Eligibility

You can join if…

Open to people ages 18-75

-Successful completion of both Treatment Period 1 and Treatment Period 2, of the CENTAUR Study (652-2-203), including a Year 2 liver biopsy.

You CAN'T join if...

  • Prior or planned liver transplantation
  • Other know causes of chronic liver disease such as: Alcoholic liver disease, Primary biliary cirrhosis, Primary sclerosing cholangitis, Autoimmune hepatitis, Wilson's disease, hemochromatosis, or iron overload, or Alpha-1-antitrypsis (A1AT) deficiency.

Locations

  • University of California, San Diego (UCSD)
    La JollaCalifornia92037United States
  • University of California, San Diego (UCSD) - Medical Center
    San DiegoCalifornia92093United States

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
Tobira Therapeutics, Inc.
ID
NCT03059446
Phase
Phase 2
Study Type
Interventional
Last Updated